Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patient... (anticoagulant therapy duringSoliris trea...)

HOME >> BIOLOGY >> TECHNOLOGY

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

Date:12/9/2008

anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing physicians are enrolled in the Soliris Safety Registry which is part of a special risk management program that involves initial and continuing education and long-term monitoring for detection of new safety findings.

Please see full prescribing information at www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris, for all patients with PNH, and Alexion began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the EC granted marketing approval for Soliris in the European Union for all patients with PNH. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for add
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C

Post Your Comments:

(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...

(Date:6/18/2013)... 2013) A million electric cars could be on roads ... the help of research by the United States Department of ... , Professor Zhongwei Chen is part of a team led ... materials to replace the expensive platinum catalysts in fuel cells. ... fuel cells in vehicles is the cost of the units. ...

(Date:6/18/2013)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing, and stem ... results for the fourth quarter and full year of ... Fourth Quarter of Fiscal 2013 Highlights , ... by 33.3% to RMB133.0 million ($21.4 million) from RMB99.8 ...

(Date:6/18/2013)... June 18, 2013 In support of ... the Consulate General of Switzerland in New York is ... Switzerland’s MS Tûranor PlanetSolar , to Manhattan. PlanetSolar ... DeepWater Expedition 2013 tour with scientists on board from ... Gérard d’Aboville, runs exclusively on energy from the sun ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City

... ... world, FAIRFAX, Va., Jan. 8 As ... ) today,announced the appointment of Timothy J. Atkin as Senior Vice President and,Mike ... Sector (GHS) organization. GHS was formed in October 2007 to,expand SRA,s footprint in ...

... HUBBARD, Ohio, Jan. 8 NanoLogix, Inc. (OTC:,NNLX), ... the company,has been named "Stock Pick of January ... vice president, stated,that "This is another example of ... We are happy to be selected by Stockprowler,-- ...

... and,momentum behind its research-and-development (R&D) pipeline has Monsanto,(NYSE: ... to farmers,by 2012, company leaders will tell investors today. ... presentations on the company,s R&D pipeline in New,York and ... the pipeline right now," said,Steve Padgette, vice president of ...

Cached Biology Technology:SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 2 SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 3 NanoLogix, Inc. Makes Stock Pick List 2 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 2 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 3

SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer NanoLogix, Inc. Makes Stock Pick List Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade

(Date:6/18/2013)... University of Calgary,s Faculty of Medicine have discovered a ... harmful bacteria. Platelets, a component of blood typically associated ... bacteria, and upon detection, seal it off from the ... in Nature Immunology this week, provide the ... "The science community has known that platelets do participate ...

(Date:6/18/2013)... Department,s National Renewable Energy Laboratory (NREL), and the ... describing a novel cellulose-degrading enzyme from a marine ... as the gribble. , Gribbles are biologically ... to produce their own enzymes instead of using ... eat. New biomass-degrading enzymes from novel sources such ...

(Date:6/18/2013)... A UT Arlington environmental engineer has been awarded ... District to ensure water quality and flow in ... Project. , Andrew Kruzic, UT Arlington associate professor ... and locations to add monochloramine to the water ... the new pump stations and pipelines. Adding monochloramine ...

Breaking Biology News(10 mins):Immunity mechanism discovered 2 Novel enzyme from tiny gribble could prove a boon for biofuels research 2 UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2

[0] Immunity mechanism discovered [0] Novel enzyme from tiny gribble could prove a boon for biofuels research [0] UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline

... Nanotechnology (IBN) have succeeded in unlocking the potential of ... converting it into a more useful product. ... the IBN researchers report that by using organocatalysts, they ... to produce methanol, a widely used industrial feedstock and ...

... blood supply to the brain is restricted. Initially, brain ... activates harmful inflammatory processes in the affected area of ... Neurology Clinic at Heidelberg University Hospital have shown that ... a stroke. These cells are known as regulatory T ...

... RIVERSIDE, Calif. A researcher at UC Riverside has discovered a ... moss or a dry leaf and named it after President ... doing a survey for lichen diversity on Santa Rosa Island in ... Herbarium . "I named it Caloplaca obamae to show ...

Cached Biology News:Singapore researchers first to transform carbon dioxide into methanol 2 'First aid' for brain cells comes from blood 2 UC Riverside researcher names lichen after President Barack Obama 2

Singapore researchers first to transform carbon dioxide into methanol 'First aid' for brain cells comes from blood UC Riverside researcher names lichen after President Barack Obama

... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...

... number is a new product number, ... number. If showing no availability yet, ... number (Z71,517-4) or contact customer service ... (expanded surface, easy grip) ...

... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...

... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ...

Biology Products:

Illumina Standard Data Analysis Report from Asuragen, Inc.CORNING 1700CM2 ROLLER BOTTLE, EASY GRIP CAP, GRADUATED, STERILE from Sigma-Aldrich CORNING ROLLER BOTTLES, 490 CM2, PS CAP, PLUG SEAL, STERILE from Sigma-Aldrich CORNING ROLLER BOTTLE WITH CELLBIND, 1700CM2, STERILE from Sigma-Aldrich